Aedifica SA AED.BR · BRU
61.30 € +0.57% (+0.35 €)
Summary
69 / 100 · Bulios Score
What speaks for it
- Out of every 100 EUR of revenue, 131 EUR is left as net profit.
- The share price is below the Bulios Fair Price.
- Revenue grew by 10% a year over the last 3 years.
- Analysts expect revenue to grow by 82% this fiscal year.
What to watch
- Earnings per share fell by 16% a year over the last 3 years.
- It passes only 2 of the 9 points of the Piotroski financial health test.
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Score in detailPrice
Is it expensive?
Looks cheapPrice against the Bulios Fair Price
P/E against its own last 5 years
P/E against the industry (REIT - Healthcare Facilities)
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Today you pay 4.7 EUR for 1 EUR of yearly profit. Over the last five years it was 32.5 EUR on average.
Valuation in detailIs it growing?
SlowlyRevenue (EUR)
Diluted EPS (EUR)
- Analyst estimate
Revenue grew by 14% a year over 5 years. Over the last 3 years it grew by 10% a year. For the next fiscal year analysts expect revenue to grow by 82%. Earnings per share fell by 16% a year over the last 3 years.
Growth in detailDoes it make money?
Very wellWhere 100 EUR of revenue goes
- Cost of sales 8.3 EUR
- Sales and administration 7.5 EUR
- Taxes and other -47 EUR
- Net profit 131 EUR
Net profit, industry median (REIT - Healthcare Facilities) 32 EUR
Out of every 100 EUR of revenue, 131 EUR is left as net profit.
Profitability in detailIs it financially healthy?
Debt is a burdenIts debt is larger than its cash. The debt score is high even so.
Financial health in detailDoes it pay a dividend?
Moderate, at risk- Yield
- 4.59%
- Paid out of profit
- 22%
- Raised in a row
- 4 years
You receive 2.80 € per share a year. The payout is more than the company can comfortably cover.
Dividends in detailWhat do analysts expect?
No coverageNo analyst covers this stock.
Analysts in detail